Shanghai Henlius Biotech Inc., (HKG: 2696) a prominent player in the biopharmaceutical industry, has published its financial results for the third quarter of 2023. The company reported revenues of RMB 3.9278 billion (USD 542 million) for the nine months ending September 30, 2023, marking an impressive 84.0% year-on-year (YOY) increase. This growth was accompanied by net profits of RMB 407.8 million (USD 56.3 million).
Q3 2023 Product Sales and Contributions
In the third quarter alone, Henlius achieved RMB 1.23 billion (USD 170 million) in product sales. Notably, the company’s biosimilar version of Roche’s Herceptin, Hanquyou (trastuzumab; HLX02), contributed RMB 737.8 million, while the anti-programmed death-1 (PD-1) monoclonal antibody HanSiZhuang (serplulimab) and Hanbeitai, a bevacizumab biosimilar, contributed RMB 309.1 million and RMB 36.4 million, respectively. Additionally, sales commissions from partnership agreements for Hanlikang (rituximab) and HanDaYuan (adalimumab) amounted to RMB 131 million and RMB 11.3 million, respectively.
Diversified Product Pipeline
Henlius Biotech prides itself on a diversified and high-quality product pipeline, encompassing over 60 molecules. This pipeline includes a range of innovative therapeutics such as monoclonal antibodies, bispecific antibodies, antibody drug conjugates (ADCs), recombinant proteins, and small molecule conjugated drugs, positioning the company at the forefront of biopharmaceutical innovation.- Flcube.com
